Your session is about to expire
← Back to Search
Peptide
Angiotensin (1-7) for Traumatic Brain Injury (ANGel T Trial)
Phase 1 & 2
Recruiting
Led By Bellal Joseph, MD
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Moderate or severe traumatic brain injury (TBI) defined as Glasgow Coma Scale (GCS) score on trauma presentation of 12 or less. In general: Moderate TBI will be defined as loss of consciousness between 30 minutes and 24 hours and GCS between 9 and 12. Severe TBI will be defined as loss of consciousness > 24 hours and GCS ≤ 9.
Age 18 years or older at time of enrollment.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up enrollment to 21 days, enrollment to 90 days
Summary
This trial aims to test the safety and effectiveness of the drug Angiotensin (1-7) in treating people with moderate to severe traumatic brain injury (TBI). Participants will receive a once
Who is the study for?
This trial is for adults who've had a moderate to severe traumatic brain injury (TBI) with a Glasgow Coma Scale score of 12 or less. They must be enrolled within 48 hours of the injury and have a CT scan confirming an acute intracranial lesion. Consent from the participant or representative is required.
What is being tested?
The trial tests Angiotensin (1-7)'s safety and effectiveness in improving mental function and reducing physical signs of TBI damage. It involves daily injections for 21 days, blood samples, two MRI scans, tasks, and questionnaires to assess brain function.
What are the potential side effects?
Potential side effects are not specified but will be monitored through health assessments during treatment with Angiotensin (1-7), comparing it against a saline placebo.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I had a serious head injury with a low consciousness score.
Select...
I am 18 years old or older.
Select...
I am signing up within 2 days after my brain injury.
Select...
I have had a head injury due to an external force.
Select...
I have a brain lesion diagnosed by a CT scan.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ enrollment to 21 days, enrollment to 90 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~enrollment to 21 days, enrollment to 90 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants with adverse events
Performance on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
Secondary study objectives
Change in suicidal ideation and behavior as assessed by the Patient Health Questionnaire (PHQ-9)
Cognitive functions after Angiotensin (1-7) treatment as measured by the Montreal Cognitive Assessment (MoCA)
Effects of Angiotensin (1-7) on CNS damage biomarker phosphorylated tau (p-tau) after 90 days
+5 moreTrial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Ang 1-7 200 mcg/kg/dayExperimental Treatment1 Intervention
Angiotensin I/II (1-7) acetate will be delivered as a subcutaneous injection at a dose of 200 micrograms per kilogram per day for 21 days.
Group II: Ang 1-7 100 mcg/kg/dayExperimental Treatment1 Intervention
Angiotensin I/II (1-7) acetate will be delivered as a subcutaneous injection at a dose of 100 micrograms per kilogram per day for 21 days.
Group III: PlaceboPlacebo Group1 Intervention
Sterile saline (NaCl) will be delivered as a subcutaneous injection for 21 days.
Find a Location
Who is running the clinical trial?
United States Department of DefenseFED
910 Previous Clinical Trials
333,641 Total Patients Enrolled
University of ArizonaLead Sponsor
536 Previous Clinical Trials
159,700 Total Patients Enrolled
Bellal Joseph, MDPrincipal InvestigatorUniversity of Arizona
2 Previous Clinical Trials
400 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger